Cancer News and Research

Latest Cancer News and Research

Annual conference to discuss male infertility and tackling falling birth rates across Europe

Male infertility and tackling falling birth rates across Europe will be among the topics addressed at this year's British Andrology Society's annual conference at Queen's University in Belfast.

19 Nov 2009

Chronic hepatitis B seems to progress faster in men, report scientists

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Their study has been published online in ACS' Journal of Proteome Research, a monthly publication.

19 Nov 2009

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa havenot been reported.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Sebelius issues statement on mammography guidelines as GOP attacks health reform proposals

ABC News: "HHS Secretary Sebelius did her best to ride the wave of incredulous opposition to the new government-sponsored guidelines advising women to hold off on regular mammograms til age 50. Perhaps anticipating that opponents of the President's health reform efforts will argue that this is a glimpse of the future under Obamacare."

19 Nov 2009

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

18 Nov 2009

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).

18 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Several studies have shown that lipid peroxidation stimulates collagen production in fibroblasts and hepatic stellate cells (HSC), and plays an important role in the development of liver fibrosis. Hepatoprotective effects of green tea against carbon tetrachloride, cholestasis and alcohol induced liver fibrosis were reported in many studies. However, the hepatoprotective effect of green tea in dimethylnitrosamine (DMN)-induced models has not been studied.

18 Nov 2009

Tempest over new mammography guidelines affect health legislation, insurance guidelines

Newspapers across the country featured front-page follow-up stories on new mammogram recommendations today.

18 Nov 2009

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.

18 Nov 2009

AT&T supports PADRES Contra El Cancer in campaign to raise awareness of childhood cancer

AT&T* today announced that it will launch the fourth annual campaign to raise awareness of childhood cancer and collect donations to support PADRES Contra El Cancer (PADRES), a nonprofit organization committed to improving the quality of life for Latino children who are battling the disease, beginning November 22. AT&T set a goal of raising $300,000 this year, which would mean a total donation of $1 million to PADRES since the campaign's inception in 2007.

18 Nov 2009

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

Roche Applied Science announces the availability of the new CIM-Plate 16 for their xCELLigence System for cell analysis, for use in cancer research. The 16-well culture plate features electronic sensors for the direct study of cell migration and invasion on the xCELLigence RTCA DP Instrument.

18 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on Power3 Medical Products, the developer of several blood tests designed for early detection, monitoring and targeting of diseases like Alzheimer's, Parkinson's and breast cancer.

18 Nov 2009

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

IBM ( IBM) announced today that its Research scientists are working with the Rizzoli Orthopedic Institute, in Bologna, Italy, to use information technology to better address treatment and research for rare genetic skeletal diseases.

18 Nov 2009

Way to capture tumor cells in the bloodstream discovered

A team led by University of Arkansas for Medical Sciences (UAMS) researchers on the cutting edge of nanotechnology has found a way to capture tumor cells in the bloodstream that could dramatically improve earlier cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Annual conference to discuss male infertility and tackling falling birth rates across Europe

Chronic hepatitis B seems to progress faster in men, report scientists

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Sebelius issues statement on mammography guidelines as GOP attacks health reform proposals

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

CEL-SCI commences clinical study of LEAPS-H1N1 treatment for hospitalized patients

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Tempest over new mammography guidelines affect health legislation, insurance guidelines

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

AT&T supports PADRES Contra El Cancer in campaign to raise awareness of childhood cancer

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Power3 Medical Products launches Phase II trials for Alzheimer's and Parkinson's diseases blood diagnostic tests

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

Way to capture tumor cells in the bloodstream discovered

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in